{"id":11035,"date":"2024-11-22T09:42:30","date_gmt":"2024-11-22T09:42:30","guid":{"rendered":"https:\/\/jubilantbiosys.com\/new-staging\/?page_id=11035"},"modified":"2026-07-03T05:39:32","modified_gmt":"2026-07-03T05:39:32","slug":"centre-of-excellence","status":"publish","type":"page","link":"https:\/\/www.jubilantbiosys.com\/new-staging\/services\/centre-of-excellence\/","title":{"rendered":"Specialised Chemistry-COE"},"content":{"rendered":"\n
\n
\n

COEs at Chemistry Innovation Research Centre for Bringing Speed and Quality to drug discovery.<\/h2>\n<\/div>\n\n\n\n

Our Centre of Excellence is designed to support expanded discovery chemistry services where we cultivate expertise in emerging methodologies.

Discover how our Centre of Excellence unites various processes and expert insights in proven and emerging approaches.<\/p>\n\n\n\n

Talk to our Experts <\/a><\/div>\n\n\n\n
\n

Our Experts Leverage their Expertise in Proven and Emerging Methodologies<\/h2>\n<\/div>\n\n\n\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

Degraders Chemistry<\/h2>\n<\/div>\n\n\n\n

Proteolysis targeting chimaeras (PROTACs), PHOTACS (photochemically targeted chimaeras) and LYTAC (lysozyme targeting chimaeras) are heterobifunctional molecules based on the combination of ubiquitin E3 ligase ligands with an inhibitor of the protein of interest (POI) via different types of linkers. With this design, the protein of interest can be degraded, which may have different biological effects compared to classical inhibition. This technique has some advantages, as it can be used for undruggable targets. Additionally, PROTACs act in very low concentrations, and they can provide increased selectivity for the target of interest rather than the original small molecule inhibitor.<\/p>\n\n\n\n

Jubilant Biosys, keeping pace with the recent developments in the field of PROTAC, PHOTAC and LYTAC, created an efficient and highly skilled group of synthetic and analytical<\/strong><\/a> chemists led by project leaders trained from various national and international premier organizations to undertake the synthesis of these complex molecules. This group can synthesise these complex molecules in a very short time with very high purity. A variety of ligands (thalidomide, lenalidomide, pomalidomide, VHL, glycopeptides) with linkers of varying sizes, synthesised internally, is used regularly for the synthesis of these compounds.<\/p>\n\n\n\n

The synthetic group is supported by a highly proficient analytical team, which purifies and analyses the intermediates and final compounds before shipping them to the clients. In the recent past, we have been able to synthesise, purify and characterise these molecules with molecular weights ranging from 450 to 2400. In addition to the synthesis of commercially available ligands on the multigram scale, we are also well-versed in developing novel structures.<\/p>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n\n

We also have an elaborate Project management group which looks after the project from the initiation to delivery. This group also takes care of all the shipment requirements especially when required under controlled conditions (~ -20o<\/sup>C).<\/p>\n\n\n\n

Click here to know more about PROTAC & LYTAC Chemistry \"click <\/a><\/div>\n\n\n\n
\n
\n

Lipid Chemistry<\/h2>\n<\/div>\n\n\n\n

The demand for lipids in pharmaceutical applications is expected to rise due to their increasing use in drug development and many other pharmaceutical applications. Lipids are a highly influential component in the development of mRNA-based vaccines for COVID-19. Its massive demand in the development of COVID-19 vaccines for the global population has compelled manufacturers to ramp up their lipid production.<\/p>\n\n\n\n

\n
\n

These are Different Types of Lipids Known in the Literature Based on their Properties<\/h3>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

Our Capabilities:<\/h2>\n<\/div>\n\n\n\n

Jubilant Biosys has over three years of rich experience in the synthesis of lipids with a dedicated team of 20-25 scientists.<\/p>\n\n\n\n

\n
\n